MedTrace Logo

Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy

NCT05107921 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2023-11-22

No results posted yet for this study

Summary

This study aims to investigate the efficacy and safety of bromfenac sodium hydrate eye drops in patients with familial exudative vitreoretinopathy receiving diode laser photocoagulation.

Conditions

  • Familial Exudative Vitreoretinopathies

Interventions

DRUG

Bromfenac Sodium

The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jeong Hun Kim, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Max Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2024-10-20
Completion
2024-10-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05107921 on ClinicalTrials.gov